Nice profile piece on Biocon’s founder. Generic insulin could work out well for PFE; the FDA regulates insulin as a small-molecule drug rather than a biologic, and hence generic versions of the insulins from NVO, LLY, and SNY would be automatically substitutable for their branded counterparts.
When PFE announced the Biocon deal in Oct 2010 (#msg-55680051), NVO’s quickly stock fell 10% (#msg-55717310).
News 
Market Data 
Discover 
AI
